ABOUT THE EVENT
Date: Tuesday, April 28, 2026 8am–6:10pm EDT
Event Location: Boston, Massachusetts
hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives from leading pharmaceutical and biotechnology organizations for a highly interactive, discussion-driven meeting focused on advancing next-generation antibody therapeutics.
This one-day forum is designed to tackle the most pressing challenges across the antibody development pipeline, including target selection and mechanisms of action, lead identification and optimization, antibody formats and scaffolds, bi/multispecific engineering, ADC linker and conjugation technologies, and ADC cytotoxic payload innovation.
Attendees will participate in roundtable discussions, pre-scheduled 1:1 meetings, expert presentations, poster sessions, and dedicated networking opportunities, enabling open exchange of scientific insight and fostering collaboration across the community.
Top industry speakers—representing global organizations such as Johnson & Johnson, RenBio, GSK, AstraZeneca, GV20 Therapeutics, Leveragen, Beam Therapeutics, Alevian, Crossbow Therapeutics, Deka BioSciences, Alexion Pharmaceuticals, ImmuVia, and others—will lead deep-dive sessions on engineering challenges, emerging technologies, safety considerations, resistance mechanisms, and strategies to accelerate antibody and ADC development.
With its unique format built for engagement rather than passive listening, Antibody Therapeutics Xchange offers an invaluable platform for scientists and decision-makers committed to advancing biologics innovation.
Seats are complimentary. For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only.
